Filing Flows › Comparisons › EBS vs XERS
Emergent BioSolutions vs Xeris Biopharma Holdings: EBS and XERS compared
Emergent BioSolutions is the larger company: $110M of revenue in its latest quarter (Q3 2026) against $107M for Xeris Biopharma Holdings (Q3 2026). Xeris Biopharma Holdings is growing faster (+44% against -52% a year earlier). Xeris Biopharma Holdings is more profitable, with an operating margin of 15.8% against -33.9%.
Where the money goes: EBS and XERS
Emergent BioSolutions (EBS) · Q3 2026
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Xeris Biopharma Holdings (XERS) · Q3 2026
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
| Emergent BioSolutions (EBS) | Xeris Biopharma Holdings (XERS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $110M | $107M |
| Revenue growth, Y/Y | -52% | +44% |
| Operating margin | -33.9% | 15.8% |
| Net earnings | −$32.7M | $11.3M |
| Net margin | -29.7% | 10.5% |
| Operating cash flow | $100M | $35.5M |
| Free cash flow | $96.8M | — |
Where the revenue comes from
Emergent BioSolutions
- MCM Product sales: $59.4M (54%)
- Commercial Product sales: $43.5M (40%)
- All other revenue: $7.1M (6%)
Xeris Biopharma Holdings
- Product revenue, net: $106M (99%)
- Royalty, contract and other revenue: $958K (1%)
Questions
Which is bigger, Emergent BioSolutions or Xeris Biopharma Holdings?
Emergent BioSolutions is the larger company: $110M of revenue in its latest quarter (Q3 2026) against $107M for Xeris Biopharma Holdings (Q3 2026).
Is Emergent BioSolutions or Xeris Biopharma Holdings growing faster?
Xeris Biopharma Holdings is growing faster (+44% against -52% a year earlier).
Which is more profitable, Emergent BioSolutions or Xeris Biopharma Holdings?
Xeris Biopharma Holdings is more profitable, with an operating margin of 15.8% against -33.9%.
More: Emergent BioSolutions earnings · how Emergent BioSolutions makes money · Xeris Biopharma Holdings earnings · how Xeris Biopharma Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.